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Kampo medicines are currently manufactured under strict quality controls. The Ministry of Health, Labour and
Welfare of Japan has approved 148 Kampo formulas. There is increasing evidence for the efficacy of Kampo medicines,
and some are used clinically for palliative care in Japan. The specific aim of this review is to evaluate the clinical use of
Kampo medicines in palliative care in the treatment of cancer. The conclusions are as follows: Juzentaihoto inhibits the
progression of liver tumors in a dose-dependent manner and contributes to long-term survival. Hochuekkito has clinical
effects on cachexia for genitourinary cancer and improves the QOL and immunological status of weak patients, such as
postoperative patients. Daikenchuto increases intestinal motility and decreases the postoperative symptoms of patients
with total gastrectomy with jejunal pouch interposition, suppresses postoperative inflammation following surgery for
colorectal cancer, and controls radiation-induced enteritis. Rikkunshito contributes to the amelioration of anorectic
conditions in cancer cachexia-anorexia syndrome. Goshajinkigan and Shakuyakukanzoto reduce the neurotoxicity
of patients with colorectal cancer who undergo oxaliplatin and FOLFOX (5-fluorouracil/folinic acid plus oxaliplatin)
therapy. Hangeshashinto has the effect of preventing and alleviating diarrhea induced by CPT-11(irinotecan) and
combination therapy with S-1/CPT-11. O’rengedokuto significantly improves mucositis caused by anticancer agents.
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Traditional Japanese medicine, including the use of Kampo
medicines, has been practiced for 1500 years. These
formulas are intended not only to help recover the
natural balance of the human body, but also treat the
body’s impairments, such as indigestion and fatigue [1].
Kampo medicine is practiced widely and is integrated
with Western medicine in Japan.
Iwase et al. [2] distributed a cross-sectional self-adminis-
tered anonymous questionnaire to 549 physicians working
in palliative care at 388 core cancer treatment hospitals
and 161 certified medical institutions with palliative
care units. In total, 311 physicians responded. They
were evenly distributed throughout the country without
significant geographical biases. Kampo medicines were
prescribed for controlling cancer-related symptoms by
64.3% of the physicians. The symptoms treated with
Kampo medicines were numbness/hypoesthesia (49.5%),
constipation (38.0%), anorexia/weight loss (36%), muscle
cramps (35.5%), and languor/fatigue (32.0%). With regard
to issues about prescription, 60.7% of the physicians raised
the issue that the dosage forms need to be better devised.* Correspondence: okuhiro@med.kindai.ac.jp
Department of Clinical Oncology, Division of Psychosomatic Medicine, Kinki
University, Faculty of Medicine, Osaka, Japan
© 2014 Okumi and Koyama; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumIto et al. [3] reported that, among 900 physicians
surveyed, 92.4% reported having prescribed Kampo
medications, 73.5% of whom reported having prescribed
them for cancer patients. Despite this high percentage
and that only 9.7% of the physicians reported that they
considered Kampo medications to be harmful, only
23.1% of the physicians expressed high expectations of
the efficacy of Kampo medicine in tumor suppression
and the exertion of immunostimulatory action.
The purpose of this paper is to investigate the clinical
use of Kampo for patients who need palliative care.
Therefore, we conducted a literature survey of current
reports on Kampo medicine use in cancer-related
treatments.Review
Prevention of malignant progression and metastasis
(Juzentaihoto, Hochuekkito)
The traditional Japanese medicine Juzentaihoto is a phar-
maceutical grade multi-herbal medicine used for the
activation of hematopoiesis and reduction of side effects
from chemotherapy and radiotherapy.
Ohnishi et al. [4] reported that oral administration of
Juzentaihoto for 7 days before tumor inoculation resultedCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and a significantly higher survival rate as compared
with the untreated control, and without side effects.
Additionally natural killer cells, macrophages, and T-cells
play important roles in the prevention of metastasis of
tumor cells and activated peritoneal exudate macrophages
to become cytostatic against the tumor cells in the host
immune system. It is suggested that Juzentaihoto inhibits
the progression of liver tumor in a dose-dependent
manner and that it contributes to long-term survival.
Hochuekkito is a Kampo formula composed of ten
crude drugs from plants. It is used for the treatment of
general fatigue caused by common colds or ordinary
life. Hochuekkito improved the quality of life (QOL)
and immunological status of elderly patients [5].
Kuroda et al. [6] performed a clinical study on 162
patients who complained of anorexia or lassitude because
of genitourinary cancer. Each patient was administered
Hochuekkito (7.5 g/day). The efficacy rate was 63.0%. The
rate of effectiveness on anorexia was 48.4% and that on
lassitude was 36.6%. Side effects were observed in 12
patients (7.4%), but most were mild gastrointestinal
disorders. No severe adverse effects were noted. This
study indicates that Hochuekkito had clinical effects on
cachexia for genitourinary cancer.
Modulation of immunological factors and surgical stress
(Hochuekkito, Daikenchuto)
Intestinal motility after gastrointestinal surgery to remove
cancer frequently is disturbed and results in postoperative
intestinal symptoms and poor QOL because gastrointes-
tinal organs modulate the immunology of the human
body.
The intestinal epithelial cells sit at the interface between
the lumen and lamina propria or lymph nodes such as
Peyer’s patches, where they maintain intestinal homeo-
stasis through chemokine secretion.
Satoh et al. [7] evaluated the effects of Hochuekkito
in the treatment of fifteen elderly patients with general
weakness. A multicenter, prospective, randomized, double-
blind, placebo-controlled study with an N of one and re-
sponder restricted design was performed. Only responders
were randomized into three groups: an active-placebo
group, a placebo-active group, and an active-active group.
The study consisted of two 6-week terms with a 2-week
washout period. The physical component summary from
the Short Form 36 Health Survey (SF-36) analysis was
significantly improved in the Hochuekkito-treated group.
Four of six components (A-H: anger-hostility, F: fatigue,
T-A: tension-anxiety, C: confusion) were improved in
the Hochuekkito-treated group in the Profile of Mood
States (POMS) analysis. Lymphocyte proliferating activity
improved in the Hochuekkito-treated group, but not
significantly. Moreover, the population of CD3 positivecells and CD3CD4 double positive cells in the surface
antigens of peripheral lymphocytes increased in the
Hochuekkito-treated group. It was suggested that
Hochuekkito improved the QOL and immunological
status of patients with weaknesses, such as postoperative
patients.
The inflammatory response after surgery is associated
with various postoperative complications. Endo et al. [8]
examined the effects of Daikenchuto on intestinal motility
and the postoperative QOL of patients. Seventeen patients
who underwent total gastrectomy with jejunal pouch
interposition for gastric cancer were assigned randomly
in the crossover study with or without Daikenchuto
using 111In-labeled liquid and 99mTc-labeled solid test
meal. In addition, a manometric study was performed to
measure contractile activity with or without Daikenchuto.
Stasis-related symptoms were reduced significantly by
Daikenchuto. In the emptying test, Daikenchuto accel-
erated the emptying of both liquid and solid meals from
the pouch. The pouch showed bursts of contractions,
which were increased significantly by the oral intake of
Daikenchuto. Daikenchuto increased intestinal motility
and decreased the postoperative symptoms of patients
with total gastrectomy with jejunal pouch interposition.
Yoshikawa et al. [9] reported the effects of Daikenchuto
on the inflammatory response of patients following laparo-
scopic colorectal resection. Thirty patients who underwent
laparoscopic colectomy for colorectal carcinoma were
divided into a Daikenchuto group (D group, 7.5 g/day
from the day after surgery until the seventh postoperative
day) and a control group (C group). The time until first
flatus was significantly shorter in the D group than in
the C group. The C reactive protein (CRP) level was
significantly lower in the D group than in the C group on
the third postoperative day. Daikenchuto administration
significantly suppressed postoperative inflammation fol-
lowing surgery for colorectal cancer.
Radiation-induced enteritis is a serious clinical problem
for which there is no current standard management.
Takeda et al. [10] evaluated a patient with radiation-
induced enteritis whose clinical symptoms were much
improved by treatment with Daikenchuto administered
orally (7.5 g/day). Abdominal distention was evaluated
objectively with computed tomography. Gastrointestinal
symptoms associated with radiation-induced enteritis were
controlled successfully with Daikenchuto. Daikenchuto
treatment may be useful for the management of radiation-
induced enteritis, according to this case study.
Nutritional support for malnourished cancer
patients (Rikkunshito)
Cachexia, a major cause of cancer-related death, is charac-
terized by depletion of muscle and fat tissues, anorexia,
asthenia, and hypoglycemia. Cachexic patients have
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induced by inflammatory cytokines.
Cheng et al. [11] reported which herbal approaches
have had associated cancer cachexia case reports. These
herbal medicines include Panax ginseng, Cimicifuga
rhizome, and Radix astragali, which are found in
Juzentaihoto, Hochuekkito, O’gonto, and Rikkunshito.
Takeda et al. [12,13] evaluated the orexigenic effect of
Rikkunshito with a focus on interaction with the ghrelin
signaling system in cancer patients with chemotherapy-
induced dyspepsia. Oral administration of Rikkunshito
potentiated the orexigenic action of ghrelin through
several different mechanisms. Human studies indicate
that Rikkunshito is a promising therapeutic option for
anorectic conditions, including cancer cachexia-anorexia
syndrome.Prevention of side effects (peripheral neuropathy,
allodynia, hyperalgesia) of paclitaxel (Goshajinkigan)
Paclitaxel is used for the treatment of solid tumors such
as those in breast, ovarian, and lung cancer. However, it
can induce peripheral neuropathy and severe muscle
dysfunction. Carboplatin/paclitaxel chemotherapy for cancer
(TC therapy) exhibits neurotoxicity and commonly causes
peripheral neuropathy, which is difficult to cope with.
Kaku et al. [14] reported the efficacy of Goshajinkigan
for patients with ovarian or endometrial cancer who
underwent TC therapy and developed peripheral neur-
opathy. Patients were randomly divided into Group A,
with 14 patients (vitamin B12 treatment), and Group B,
with 15 patients (vitamin B12 +Goshajinkigan treatment).
The observation period was 6 weeks following treatment
initiation, and the evaluation items were as follows: i)
current perception threshold of the peripheral nerve, ii)
visual analogue scale for numbness, iii) grade of neuro-
toxicity, and iv) subjective symptoms of peripheral
neuropathy. Items were compared between the groups
and no significant differences were noted in any item.
However, neurotoxicity developed in some patients
Group A after 6 weeks, whereas no neurotoxicity was
observed in Group B. Moreover, the frequency of abnor-
mal values was significantly lower in Group B than in
Group A. Therefore, Goshajinkigan may inhibit the
progression of peripheral neuropathy after chemotherapy.Prevention of a peripheral neuropathy from oxaliplatin
(Goshajinkigan, Shakuyaku- kanzoto)
Oxaliplatin is used in the treatment of colorectal cancer,
but it causes acute and chronic neuropathies. Peripheral
neurotoxicity is the major limiting factor for oxaliplatin
therapy. Goshajinkigan is a Kampo medicine used for
the treatment of several neurological symptoms, includ-
ing pain and numbness. More recently, the formula hasbeen reported to clinically prevent oxaliplatin-induced
peripheral neuropathy.
A combination of 5-fluorouracil/folinic acid plus oxalipla-
tin (FOLFOX) is a standard regimen for the chemotherapy
of metastatic colorectal cancer. The major dose-limiting
toxic effect of oxaliplatin is neurotoxicity. Kono et al. [15]
retrospectively investigated the effect of Goshajinkigan
on peripheral neurotoxicity associated with oxaliplatin
therapy. Ninety patients with metastatic colorectal cancer
who received FOLFOX6 therapy were assigned to receive
one of the following adjuncts: oral Goshajinkigan (7.5 g/
day) (Group A), intravenous supplementation of calcium
gluconate and magnesium sulfate (1 g each before and
after FOLFOX) (Group B), Goshajinnkigan, calcium glu-
conate, and magnesium sulfate therapies (Group C), or
no concomitant therapy (Group D). The incidence of
peripheral neurotoxicity was investigated when the
cumulative dose of oxaliplatin exceeded 500 mg/m2. When
the cumulative dose of oxaliplatin exceeded 500 mg/m2,
the incidence of neuropathy (all grades) in Groups A–D
was 50.0, 100, 78.9, and 91.7%, respectively. It was lowest
in the group that received Goshajinkigan alone. Con-
comitant administration of Goshajinkigan reduced the
neurotoxicity of oxaliplatin in patients who received
chemotherapy for colorectal cancer.
Hosokawa et al. [16] evaluated the preventive effects of
Goshajinkigan and Shakuyaku- kanzoto on oxaliplatin-
induced neurotoxicity with FOLFOX. Patients with meta-
static colorectal cancer who received modified FOLFOX6
or FOLFOX4 for three years received either Goshajinkigan
(group A) or Shakuyakukanzoto (group B). The response
rate of the 38 patients with measurable lesions was 50.0%
(9/18) in group A and 65% (13/20) in group B, in the
cumulative dose exceeding 500 mg/m2. The adminis-
tration of traditional Japanese medicine may reduce
oxaliplatin-induced neurotoxicity without negatively
affecting tumor response in patients with colorectal
cancer who undergo FOLFOX therapy.
Prevention of diarrhea from irinotecan (Hangeshashinto)
The chemotherapeutic agent CPT-11 (irinotecan) has
shown promising results as a single agent and in com-
bination chemotherapy for the treatment of colorectal and
small cell lung cancer. Preventing CPT-11-induced delayed
diarrhea, oral alkalization, and control of defecation has
been studied. Oral administration of antibiotics or Kampo
medicine to decrease beta-glucuronidase activity derived
from bacteria in the large intestine was reported to be
successful in preventing delayed diarrhea. When CPT-
11-induced delayed diarrhea occurs, the conventional
treatment is loperamide [17].
Mori K et al. [18] conducted a randomized comparative
trial of 41 previously untreated patients with advanced
non-small-cell lung cancer to investigate whether support
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induced diarrhea. The chemotherapy regimen consisted
of a combination of cisplatin and CPT-11. TJ-14 (7.5 g/
day) was administered orally. Compared with the control
group, although no differences in the frequency of diarrhea
or the number of days the symptoms continued, the
Hangeshashinto group showed a significant improve-
ment in diarrhea grades (P = 0.044) as well as a reduced
frequency of diarrhea grades 3 and 4 (one patient versus
ten patients; P = 0.018).
It is suggested that Hangeshashinto, which contains
baicalin, a beta-glucuronidase inhibitor, alleviates diarrhea
induced by CPT-11.
Hibi et al. [19] prospectively investigated the influence
of Hangeshashinto on the therapeutic and adverse effects
of chemotherapy and the changes in QOL scores of
patients with metastatic gastric and colorectal cancer
from 2007 to 2008. Twenty patients receiving S-1/CPT-11
therapy were randomly allocated into group A (with
Hangeshashinto) and B (control). While the anti-tumor
effects did not differ significantly between these two
groups, severe side effects of more than grade 3 occurred
less frequently in group A. Moreover, the decrease in
QOL scores on day 15 were improved in group A com-
pared to group B. Therefore, Hangeshashinto could be
used as a supportive medicine in the combination therapy
of S-1/CPT-11.
Prevention of other side effects from chemotherapy
(O’rengedokuto)
Most anticancer agents cause xerostomia and mucositis,
such as stomatitis and gastrointestinal mucosal injury,
which is associated with infections, a decrease in QOL,
and discontinuation of chemotherapy in patients with
malignancy.
Yuki et al. [20] retrospectively evaluated the preventive
effect of the oral administration of O’rengedokuto on
stomatitis and diarrhea induced by cytotoxic drugs in 40
patients with acute leukemia. The incidence of stomatitis
was 27.9% in the group given O’rengedokuto, which was
significantly lower compared with 71.6% of those who
received a gargle consisting of allopurinol, sodium guale-
nate, and povidone iodine. Drug-induced diarrhea was
observed in 9.3% of the O’rengedokuto group compared
with 31.7% of the control group. These observations
indicate that O’rengedokuto significantly improved mu-
cositis caused by anticancer agents.
Others
Several reports have presented the efficacy of Kampo
medicines on palliative care. Some clinical articles about
Kampo medicine have reported the effect of Bakumondoto
on dry cough and thirst, Hangekobokuto on dysphasia
and depression, Kikyoto on stomatitis and pharyngealpain involved in radiotherapy, and Yokukansan on delirium
in palliative care.
Some basic research indicates that bone marrow sup-
pression by treatment with TS-1 might be improved by
the coadministration of Juzentaihoto or Ninjin’yoeito.
Juzentaihoto also could be an effective drug for protecting
against the side effects induced by cisplatin and carboplatin.
These formulas are known as “Hozai” or “Rikizai” and
are used to activate hematopoiesis and treat anorexia in
Japan, but there is a lack of the evidence for their effective-
ness in clinical palliative care.
Conclusions
Many palliative care physicians prescribed Kampo medicine
because of the expectation that it would control the
symptoms or adverse side effects of chemotherapy for
cancer patients. The concepts on which Kampo (oriental)
medicines are prescribed are much different from those of
Western medicine. Physicians who specialize in Kampo
medicine traditionally prescribe formulas based on the
status of the physical and mental aspects of the patient
(Sho). However, most palliative care physicians have no
experience with Kampo medicine and must depend on
evidence for drug efficacy. The prescription of Kampo
formulas is limited because of the lack of evidence-based
reports.
More evidence from clinical studies is desirable, and
further research into the efficacy of Kampo medicine for
cancer patients is warranted in Japan.
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